The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals (SEHK:2616) for $44 million on December 21, 2023. This will be followed by a payment of up to 6 million USD upon completion of the transition. As a result, the licensing agreement with Servier will be terminated and CStone will be released from payment obligations of any remaining development and commercialization milestones.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 HKD | +2.70% |
|
+4.59% | -49.78% |
18/06 | CStone Pharmaceuticals Announces Change of Joint Company Secretary | CI |
13/06 | CStone Gets Green Light for Local Manufacturing of AYVAKIT in China | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.78% | 19Cr | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+17.23% | 2.6TCr | |
-23.86% | 1.94TCr | |
-19.44% | 1.59TCr | |
-20.90% | 1.51TCr | |
-46.14% | 1.51TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.39TCr |
- Stock Market
- Equities
- 2616 Stock
- News CStone Pharmaceuticals
- The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals for $44 million.